|
End-of-day quote
Shanghai S.E.
02/11/2026
|
5-day change | 1st Jan Change | ||
| 4.660 CNY | +2.42% |
|
-2.71% | -15.73% |
Company Valuation: North China Pharmaceutical Company.Ltd
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 16,781 | 20,452 | 10,981 | 9,780 | 8,870 | 9,488 |
| Change | - | 21.87% | -46.31% | -10.94% | -9.3% | 6.96% |
| Enterprise Value (EV) 1 | 25,126 | 28,923 | 20,346 | 19,939 | 18,660 | 19,162 |
| Change | - | 15.11% | -29.65% | -2% | -6.41% | 2.69% |
| P/E | 172x | 1,084x | -15.9x | 1,900x | 69.9x | 51.7x |
| PBR | 2.74x | 3.36x | 2.07x | 1.84x | 1.65x | 1.72x |
| PEG | - | -13.3x | 0x | -19x | 0x | 1.2x |
| Capitalization / Revenue | 1.46x | 1.97x | 1.05x | 0.97x | 0.9x | 1.03x |
| EV / Revenue | 2.19x | 2.79x | 1.94x | 1.97x | 1.89x | 2.07x |
| EV / EBITDA | 20.8x | 23.7x | 15.2x | 15.7x | 12.9x | 12.6x |
| EV / EBIT | 42x | 48.2x | 32.1x | 37.2x | 28.3x | 30.6x |
| EV / FCF | -30.9x | -32x | 112x | 128x | 49.1x | 35.2x |
| FCF Yield | -3.24% | -3.12% | 0.89% | 0.78% | 2.03% | 2.84% |
| Dividend per Share 2 | 0.03 | 0.06 | - | 0.01 | 0.03 | 0.035 |
| Rate of return | 0.29% | 0.5% | - | 0.18% | 0.58% | 0.63% |
| EPS 2 | 0.06 | 0.011 | -0.402 | 0.003 | 0.074 | 0.107 |
| Distribution rate | 50% | 545% | - | 333% | 40.5% | 32.7% |
| Net sales 1 | 11,493 | 10,385 | 10,500 | 10,120 | 9,870 | 9,242 |
| EBITDA 1 | 1,209 | 1,221 | 1,343 | 1,272 | 1,447 | 1,517 |
| EBIT 1 | 597.9 | 600.1 | 634.8 | 536.4 | 658.9 | 627.2 |
| Net income 1 | 97.32 | 18.73 | -689.2 | 4.89 | 127 | 183.1 |
| Net Debt 1 | 8,345 | 8,472 | 9,366 | 10,159 | 9,790 | 9,674 |
| Reference price 2 | 10.290 | 11.920 | 6.400 | 5.700 | 5.170 | 5.530 |
| Nbr of stocks (in thousands) | 16,30,805 | 17,15,730 | 17,15,730 | 17,15,730 | 17,15,730 | 17,15,730 |
| Announcement Date | 28/04/21 | 27/04/22 | 21/04/23 | 29/03/24 | 27/03/25 | 17/04/26 |
1CNY in Million2CNY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 117.29Cr | ||
| 41.42x | 14.01x | 31.06x | 0.48% | 1,26300Cr | ||
| 39.99x | 6.71x | 18.89x | 1.95% | 66TCr | ||
| 36.71x | 8.6x | 17.71x | 2.35% | 52TCr | ||
| 21.74x | 5.27x | 13.12x | 2.48% | 39TCr | ||
| 97.38x | 6.07x | 25.8x | 2.28% | 37TCr | ||
| 23.19x | 5.95x | 14.36x | 2.69% | 31TCr | ||
| 24.47x | 4.89x | 13.87x | 1.77% | 29TCr | ||
| 29.55x | 7.53x | 13.48x | 2.16% | 25TCr | ||
| -40.86x | 7.45x | 46.76x | 1.94% | 21TCr | ||
| Average | 30.40x | 7.39x | 21.67x | 2.01% | 42.63TCr | |
| Weighted average by Cap. | 36.41x | 8.82x | 22.82x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 600812 Stock
- Valuation North China Pharmaceutical Company.Ltd
Select your edition
All financial news and data tailored to specific country editions
















